CN111902400B - 芳香族衍生物其制备方法和医学用途 - Google Patents

芳香族衍生物其制备方法和医学用途 Download PDF

Info

Publication number
CN111902400B
CN111902400B CN202080000743.2A CN202080000743A CN111902400B CN 111902400 B CN111902400 B CN 111902400B CN 202080000743 A CN202080000743 A CN 202080000743A CN 111902400 B CN111902400 B CN 111902400B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
tautomer
stereoisomer
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080000743.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111902400A (zh
Inventor
邵宁
王丁
袁宏斌
弗兰克.凯泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bosgene Biotechnology Shanghai Co ltd
Original Assignee
Bosgene Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bosgene Biotechnology Shanghai Co ltd filed Critical Bosgene Biotechnology Shanghai Co ltd
Publication of CN111902400A publication Critical patent/CN111902400A/zh
Application granted granted Critical
Publication of CN111902400B publication Critical patent/CN111902400B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN202080000743.2A 2019-03-05 2020-02-19 芳香族衍生物其制备方法和医学用途 Active CN111902400B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/076926 2019-03-05
PCT/CN2019/076926 WO2020177067A1 (en) 2019-03-05 2019-03-05 Aromatic derivatives, preparation methods, and medical uses thereof
PCT/CN2020/075849 WO2020177534A1 (en) 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof

Publications (2)

Publication Number Publication Date
CN111902400A CN111902400A (zh) 2020-11-06
CN111902400B true CN111902400B (zh) 2024-08-30

Family

ID=72337401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080000743.2A Active CN111902400B (zh) 2019-03-05 2020-02-19 芳香族衍生物其制备方法和医学用途

Country Status (10)

Country Link
US (1) US11976058B2 (cg-RX-API-DMAC7.html)
EP (1) EP3935048A4 (cg-RX-API-DMAC7.html)
JP (1) JP7470708B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210135558A (cg-RX-API-DMAC7.html)
CN (1) CN111902400B (cg-RX-API-DMAC7.html)
CA (1) CA3132405A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552133A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109522VA (cg-RX-API-DMAC7.html)
TW (1) TWI860334B (cg-RX-API-DMAC7.html)
WO (2) WO2020177067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595370B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US10935695B2 (en) 2018-03-02 2021-03-02 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US12595371B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Contact lens with improved vision break-up time
US12674032B2 (en) 2019-06-28 2026-07-07 Johnson & Johnson Vision Care, Inc. Polymerizable fused tricyclic compounds as absorbers of UV and visible light
US20220194944A1 (en) * 2020-12-18 2022-06-23 Johnson & Johnson Vision Care, Inc. Photostable mimics of macular pigment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997637B (zh) * 2017-09-05 2022-09-27 保仕健生物科技(上海)有限公司 芳香类衍生物、其制备方法及其在医药上的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
NZ703495A (en) * 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2015108992A1 (en) * 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
JP6655559B2 (ja) 2014-06-24 2020-02-26 コベストロ、ドイチュラント、アクチエンゲゼルシャフトCovestro Deutschland Ag ジフェニルメタン系ジアミンおよびポリアミンの製造方法
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3029864B1 (en) 2014-12-01 2020-11-18 Harman Becker Automotive Systems GmbH Fast representation of station information in a fm receiver using a single tuner
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) * 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105906630B (zh) 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
CN107286130A (zh) * 2016-04-13 2017-10-24 成都融科博海科技有限公司 一种激酶选择性抑制剂
RU2747260C2 (ru) * 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
CN109224235B (zh) 2018-10-23 2020-05-19 孙喜家 一种双腔管
CN109331654A (zh) 2018-10-26 2019-02-15 高邮高和光电器材有限公司 一种有机废气光催化氧化装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997637B (zh) * 2017-09-05 2022-09-27 保仕健生物科技(上海)有限公司 芳香类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
SG11202109522VA (en) 2021-09-29
WO2020177067A1 (en) 2020-09-10
US20220169634A1 (en) 2022-06-02
CN111902400A (zh) 2020-11-06
US11976058B2 (en) 2024-05-07
WO2020177534A1 (en) 2020-09-10
PH12021552133A1 (en) 2022-08-22
CA3132405A1 (en) 2020-09-10
EP3935048A1 (en) 2022-01-12
EP3935048A4 (en) 2022-11-09
KR20210135558A (ko) 2021-11-15
TWI860334B (zh) 2024-11-01
JP2022522890A (ja) 2022-04-20
TW202100514A (zh) 2021-01-01
JP7470708B2 (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
US12083124B2 (en) Bicyclic heterocycles as FGFR inhibitors
US11530218B2 (en) Spiro compounds as inhibitors of KRAS
AU2020256431B2 (en) Bicyclic heterocycles as fgfr4 inhibitors
TWI860334B (zh) 芳香族衍生物、包括其之藥物組合物與試劑盒及其用途
US11566028B2 (en) Bicyclic heterocycles as FGFR inhibitors
US10899755B2 (en) Benzothiazole compounds and uses thereof
US9840503B2 (en) Heterocyclic compounds and uses thereof
WO2016064960A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
US12428420B2 (en) Tricyclic heterocycles as FGFR inhibitors
CA3220274A1 (en) Tricyclic heterocycles as fgfr inhibitors
US10723705B2 (en) Heterocyclic compounds and uses thereof
WO2019074824A1 (en) INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
HK40040054B (en) Aromatic derivatives, preparation methods, and medical uses thereof
HK40040054A (en) Aromatic derivatives, preparation methods, and medical uses thereof
HK40104086A (en) Mcl-1 inhibitors
TW202545531A (zh) 氮—喹唑啉化合物之使用方法
HK1227022B (en) Serine/threonine kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20201106

Assignee: Beijing shengnuoji Pharmaceutical Technology Co.,Ltd.

Assignor: Bosgene Biotechnology (Shanghai) Co.,Ltd.

Contract record no.: X2020990000648

Denomination of invention: Aromatic derivatives, preparation method and medical use thereof

License type: Exclusive License

Record date: 20201201

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040054

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant